1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail. 2008;10:933–89. [PubMed] [Google Scholar]
2. Hsu DT, Pearson GD. Heart failure in children: Part I: History, etiology, and pathophysiology. Circ Heart Fail. 2009;2:63–70. [PubMed] [Google Scholar]
3. Kay JD, Colan SD, Graham TP., Jr Congestive heart failure in pediatric patients. Am Heart J. 2001;142:923–8. [PubMed] [Google Scholar]
4. Massin MM, Astadicko I, Dessy H. Epidemiology of heart failure in a tertiary pediatric center. Clin Cardiol. 2008;31:388–91. [PMC free article] [PubMed] [Google Scholar]
5. Rossano JW, Kim JJ, Decker JA, Price JF, Zafar F, Graves DE, et al. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: A population-based study. J Card Fail. 2012;18:459–70. [PubMed] [Google Scholar]
6. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348:1647–55. [PubMed] [Google Scholar]
7. Andrews RE, Fenton MJ, Ridout DA, Burch M. British Congenital Cardiac Association. New-onset heart failure due to heart muscle disease in childhood: A prospective study in the United Kingdom and Ireland. Circulation. 2008;117:79–84. [PubMed] [Google Scholar]
8. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867–76. [PubMed] [Google Scholar]
9. Chaturvedi V, Saxena A. Heart failure in children: Clinical aspect and management. Indian J Pediatr. 2009;76:195–205. [PubMed] [Google Scholar]
10. Ross RD, Bollinger RO, Pinsky WW. Grading the severity of congestive heart failure in infants. Pediatr Cardiol. 1992;13:72–5. [PubMed] [Google Scholar]
11. Satou GM, Lacro RV, Chung T, Gauvreau K, Jenkins KJ. Heart size on chest x-ray as a predictor of cardiac enlargement by echocardiography in children. Pediatr Cardiol. 2001;22:218–22. [PubMed] [Google Scholar]
12. Azevedo VM, Santos MA, Albanesi Filho FM, Castier MB, Tura BR, Amino JG. Outcome factors of idiopathic dilated cardiomyopathy in children – A long-term follow-up review. Cardiol Young. 2007;17:175–84. [PubMed] [Google Scholar]
13. Cianfrocca C, Pelliccia F, Nigri A, Critelli G. Resting and ambulatory ECG predictors of mode of death in dilated cardiomyopathy. J Electrocardiol. 1992;25:295–303. [PubMed] [Google Scholar]
14. Van der Hauwaert LG, Denef B, Dumoulin M. Long-term echocardiographic assessment of dilated cardiomyopathy in children. Am J Cardiol. 1983;52:1066–71. [PubMed] [Google Scholar]
15. Hammerer-Lercher A, Geiger R, Mair J, Url C, Tulzer G, Lechner E, et al. Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. Clin Chem. 2006;52:1415–9. [PubMed] [Google Scholar]
16. Deshpande SR. B-type natriuretic peptide at presentation of dilated cardiomyopathy in children predicts outcome. Congenit Heart Dis. 2011;6:539–40. [Google Scholar]
17. Law YM, Keller BB, Feingold BM, Boyle GJ. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol. 2005;95:474–8. [PubMed] [Google Scholar]
18. Hongkan W, Soongswang J, Veerakul G, Sanpakit K, Punlee K, Rochanasiri W, et al. N-terminal pro brain natriuretic peptide and cardiac function in doxorubicin administered pediatric patients. J Med Assoc Thai. 2009;92:1450–7. [PubMed] [Google Scholar]
19. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J. 2005;26:1197–202. [PubMed] [Google Scholar]
20. Kindel SJ, Miller EM, Gupta R, Cripe LH, Hinton RB, Spicer RL, et al. Pediatric cardiomyopathy: Importance of genetic and metabolic evaluation. J Card Fail. 2012;18:396–403. [PMC free article] [PubMed] [Google Scholar]
21. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term follow-up of biopsy-proven viral myocarditis: Predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59:1604–15. [PubMed] [Google Scholar]
22. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33. [PubMed] [Google Scholar]
23. Ratnapalan S, Griffiths K, Costei AM, Benson L, Koren G. Digoxin-carvedilol interactions in children. J Pediatr. 2003;142:572–4. [PubMed] [Google Scholar]
24. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol. 1993;14:9–12. [PubMed] [Google Scholar]
25. Leversha AM, Wilson NJ, Clarkson PM, Calder AL, Ramage MC, Neutze JM. Efficacy and dosage of enalapril in congenital and acquired heart disease. Arch Dis Child. 1994;70:35–9. [PMC free article] [PubMed] [Google Scholar]
26. Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis Child. 1988;63:360–3. [PMC free article] [PubMed] [Google Scholar]
27. Frenneaux M, Stewart RA, Newman CM, Hallidie-Smith KA. Enalapril for severe heart failure in infancy. Arch Dis Child. 1989;64:219–23. [PMC free article] [PubMed] [Google Scholar]
28. Kirk R, Dipchand AI, Rosenthal DN, Addonizio L, Burch M, Chrisant M, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary.[Corrected] J Heart Lung Transplant. 2014;33:888–909. [PubMed] [Google Scholar]
29. Kantor PF, Lougheed J, Dancea A, McGillion M, Barbosa N, Chan C, et al. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol. 2013;29:1535–52. [PubMed] [Google Scholar]
30. Blume ED, Canter CE, Spicer R, Gauvreau K, Colan S, Jenkins KJ. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol. 2006;27:336–42. [PubMed] [Google Scholar]
31. Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol. 2002;40:2034–8. [PubMed] [Google Scholar]
32. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al. Carvedilol for children and adolescents with heart failure: A randomized controlled trial. JAMA. 2007;298:1171–9. [PubMed] [Google Scholar]
33. Foerster SR, Canter CE. Pediatric heart failure therapy with beta-adrenoceptor antagonists. Paediatr Drugs. 2008;10:125–34. [PubMed] [Google Scholar]
34. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107:996–1002. [PubMed] [Google Scholar]
35. Egan JR, Clarke AJ, Williams S, Cole AD, Ayer J, Jacobe S, et al. Levosimendan for low cardiac output: A pediatric experience. J Intensive Care Med. 2006;21:183–7. [PubMed] [Google Scholar]
36. Namachivayam P, Crossland DS, Butt WW, Shekerdemian LS. Early experience with Levosimendan in children with ventricular dysfunction. Pediatr Crit Care Med. 2006;7:445–8. [PubMed] [Google Scholar]
37. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2013;127:e283–352. [PubMed] [Google Scholar]
38. Duncan BW, Bohn DJ, Atz AM, French JW, Laussen PC, Wessel DL. Mechanical circulatory support for the treatment of children with acute fulminant myocarditis. J Thorac Cardiovasc Surg. 2001;122:440–8. [PubMed] [Google Scholar]
39. Stiller B, Dähnert I, Weng YG, Hennig E, Hetzer R, Lange PE. Children may survive severe myocarditis with prolonged use of biventricular assist devices. Heart. 1999;82:237–40. [PMC free article] [PubMed] [Google Scholar]
40. Kirk R, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Dobbels F, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirteenth official pediatric heart transplantation report – 2010. J Heart Lung Transplant. 2010;29:1119–28. [PubMed] [Google Scholar]
41. Ringewald JM, Gidding SS, Crawford SE, Backer CL, Mavroudis C, Pahl E. Nonadherence is associated with late rejection in pediatric heart transplant recipients. J Pediatr. 2001;139:75–8. [PubMed] [Google Scholar]
Page 2
Causes of over circulation heart failure